Peritumoral AMs, which promote tumor growth by secreting IL‐10 and CCL2, have been implicated in poor prognosis in patients with lung metastases of non‐pulmonary origin and those with primary lung adenocarcinoma [35, 36]. Here, CCL2 is linked to neoplasm.